Denmark based pharmaceutical firm Novo Nordisk today launched its combination diabetic drug Ryzodeg, priced at Rs. 1,595 for 300 units, for people with type II diabetes in India.
Apart from India, Ryzodeg has been approved for marketing in Aruba, Brazil, Chile, Costa Rica, El Salvador, EU, Hong Kong, Iceland, Israel, Japan, Kazakhstan, Macedonia, Mexico, Norway, Russia, South Korea and Switzerland, Novo Nordisk said.
Novo Nordisk Corporate VP for Business Area Africa, Gulf & India, Mads Bo Larsen said: “India has close to 65.1 million people with diabetes standing second in the world map. We are extremely pleased to have introduced Ryzodeg reinforcing our commitment to provide best of healthcare solutions for the use of doctors in India.”
As Ryzodeg is a combination product it requires fewer daily injections than administering basal and mealtime insulin in separate injections, Novo Nordisk said.
“For more than 90 years, Novo Nordisk has been leading the fight against diabetes by developing the most innovative products based on patient needs. The launch of Ryzodeg builds on this heritage as it is an innovative product that will give the healthcare professional a better way to manage the condition,” Novo Nordisk India MD Melvin Oscar D’souza said.
The product is a combination of two distinct insulin analogues (insulin degludec and insulin aspart in the ratio of 70 per cent and 30 per cent), the company said.
Diabetes is a group of diseases marked by high levels of blood sugar (glucose) caused by problems with the body’s ability to produce or properly use insulin, or both.PTI
